Suppression of cerebrospinal fluid HIV burden in antiretroviral naive patients on a potent four-drug antiretroviral regimen

AIDS

Volumn 17, Issue 8, 2003, Pages 1167-1172

  Polis, Michael A ^a   Suzman, Daniel L ^a   Yoder, Christian P ^b   Shen, Jean M ^b   Mican, JoAnn M ^a   Dewar, Robin L ^c   Metcalf, Julia A ^a   Falloon, Judith ^a   Davey Jr , Richard T ^a   Kovacs, Joseph A ^b   Feinberg, Mark B ^d   Masur, Henry ^b   Piscitelli, Stephen C ^b  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c SAIC FREDERICK INC   (United States)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

AIDS; Antiretroviral therapy; Cerebrospinal fluid; HIV; Protease inhibitors; Viral load

Indexed keywords

ANTIRETROVIRUS AGENT; INDINAVIR; LAMIVUDINE; NEVIRAPINE; PROTEINASE INHIBITOR; VIRUS RNA; ZIDOVUDINE;

ADULT; ARTICLE; BLOOD ANALYSIS; CELL COUNT; CENTRAL NERVOUS SYSTEM; CEREBROSPINAL FLUID ANALYSIS; CLINICAL ARTICLE; CYTOCHEMISTRY; DRUG BRAIN LEVEL; DRUG PENETRATION; DRUG POTENCY; FEMALE; HEALTH CENTER; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LEUKOCYTE; LONGITUDINAL STUDY; LUMBAR PUNCTURE; MALE; MEDICAL EXAMINATION; OPEN STUDY; PRIORITY JOURNAL; RASH; VIRUS LOAD;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; FOLLOW-UP STUDIES; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; INDINAVIR; LEUKOCYTE COUNT; RNA, VIRAL; VIRAL LOAD;

EID: 0038544086     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200305230-00008     Document Type: Article

References (31)

1. Ellis RJ, Hsia K, Spector SA, Nelson JA, Heaton RK, Wallace MR, et al. Cerebrospinal fluid human immunodeficiency virus type 1 RNA levels are elevated in neurocognitively impaired individuals with acquired immunodeficiency syndrome. Ann Neurol 1997, 42:679-688.
2. McArthur JC, McClernon DR, Cronin MF, Nance-Sproson TE, Saah A, St. Clair M, et al. Relationship between human immunodeficiency virus-associated dementia and viral load in cerebrospinal fluid and brain. Ann Neurol 1997, 42:689-698.
3. Dore GJ, Correll PK, Li Y, Kaldor JM, Cooper DA, Brew BJ, et al. Changes to AIDS dementia complex in the era of highly active antiretroviral therapy. AIDS 1999, 13:1249-1253.
4. Dore GJ, Li YM, McDonald A, Ree H, Kaldor JM, National Surveillance Committee. Impact of highly active antiretroviral therapy on individual AIDS-defining illness incidence and survival in Australia. J Acquir Immune Def Syndr 2002, 29:388-395.
5. Woolf E, Haddix HM, Matuszewski B. Determination of an in vivo metabolite of a human immunodeficiency virus protease-inhibitor in human plasma by high-performance liquid chromatography with tandem mass spectrometry. J Chromatogr 1997, 762:311-319.
6. Crixivan (indinavir) product information, Merck & Co., Inc, West Point, PA, 2002.
7. Foudraine NA, Hoetelmans RMW, Lange JMA, de Wolf F, van Benthem BHB, Maas JJ, et al. Cerebrospinal fluid HIV-1 RNA and drug concentrations after treatment with lamivudine plus zidovudine or stavudine. Lancet 1998, 351:1547-1551.
8. Gisslen M, Svennerholm B, Norkrans G, Franzen C, Sall C, Svensson R, et al. Cerebrospinal fluid and plasma viral load in HIV-1-infected patients with various anti-retroviral treatment regimens. Scand J Infect Dis 2000, 32:365-369.
9. Garcia F, Niebla G, Romeu J, Vidal C, Plana M, Ortega M, et al. Cerebrospinal fluid HIV-1 RNA levels in asymptomatic patients with early stage chronic HIV-1 infection: support for the hypothesis of local virus replication. AIDS 1999, 13:1491-1496.
10. Staprans S, Marlowe N, Glidden D, Novakovic-Agopian T, Grant RM, Heyes M, et al. Time course of cerebrospinal fluid responses to antiretroviral therapy: evidence for variable compartmentalization of infection. AIDS 1999, 13:1051-1061.
11. Enting RH, Prins JM, Jurriaans S, Brinkman K, Portegies P, Lange JM. Concentrations of human immunodeficiency virus type 1 (HIV-1) RNA in cerebrospinal fluid after antiretroviral treatment initiated during primary HIV-1 infection. Clin Infect Dis 2001, 32:1095-1099.
12. Kerza-Kwiatecki AP, Amini S. CNS as an HIV-1 reservoir; BBB and drug delivery. J Neurovirol 1999, 5:113-114.
13. Price RW, Staprans S. Measuring the "viral load" in cerebrospinal fluid in human immunodeficiency virus infection: window into brain infection? Ann Neurol 1997, 42:675-678.
14. Haas DW, Clough LA, Johnson BW, Harris VL, Spearman P, Wilkinson GR, et al. Evidence of a source of HIV type 1 within the central nervous system by ultraintensive sampling of cerebrospinal fluid and plasma. AIDS Res Hum Retroviruses 2000, 16:1491-1502.
15. Ståhle L, Martin C, Svensson JO, Sonnerborg A. Indinavir in cerebrospinal fluid of HIV-1-infected patients [letter]. Lancet 1997, 350:1823.
16. Martin C, Sönnerborg A, Svensson JO, Ståhle L. Indinavir-based treatment of HIV-1 infected patients: efficacy in the central nervous system. AIDS 1999, 13:1227-1232.
17. Letendre SL, Capparelli EV, Ellis RJ, McCutchan JA. Indinavir population pharmacokinetics in plasma and cerebrospinal fluid. The HIV Neurobehavioral Research Center Group. Antimicrob Agents Chemother 2000, 44:2173-2175.
18. Zhou XJ, Havlir DV, Richman DD, Acosta EP, Hirsch M, Collier AC, et al. Plasma population pharmacokinetics and penetration into cerebrospinal fluid of indinavir in combination with zidovudine and lamivudine in HIV-1-infected patients. AIDS 2000, 14:2869-2876.
19. Aweeka F, Jayewardene A, Staprans S, Bellibas SE, Kearney B, Lizak P, et al. Failure to detect nelfinavir in the cerebrospinal fluid of HIV-1 infected patients with and without AIDS dementia complex. J Acquir Immune Defic Syndr Hum Retrovirol 1999, 20:39-43.
20. Haas DW, Stone J, Clough LA, Johnson B, Spearman P, Harris VL, et al. Steady-state pharmacokinetics of indinavir in cerebrospinal fluid and plasma among adults with human immunodeficiency virus type I infection. Clin Pharmacol Ther 2000, 68:367-374.
21. Kim RB, Fromm MF, Wandel C, Leake B, Wood AJJ, Roden, DM, et al. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest 1998, 101:289-294.
22. Rolinski B, Bogner JR, Sadri I, Wintergerst U, Goebel F. Absorption and elimination kinetics of zidovudine in the cerebrospinal fluid in HIV-1-infected patients. J Acquir Immune Defic Syndr Hum Retrovirol 1997, 15:192-197.
23. Haworth SJ, Christofalo B, Anderson RD, Dunkle LM. A single-dose study to assess the penetration of stavudine into human cerebrospinal fluid in adults. J Acquir Immune Defic Syndr Hum Retrovirol 1998, 17:235-238.
24. Davis LE, Hjelle BL, Miller VE, Palmer DL, Llewellyn AL, Merlin TL, et al. Early viral brain invasion in iatrogenic human immunodeficiency virus infection. Neurology 1992, 42:1736-1739.
25. Ellis RJ, Moore DJ, Childers ME, Letendre S, McCutchan JA, Wolfson T, et al. Progression to neurological impairment in human immunodeficiency virus infection predicted by elevated cerebrospinal fluid levels of human immunodeficiency virus RNA. Arch Neurol 2002, 59:909-912.
26. Eggers CC, van Lunzen J, Buhk T, Stellbrink HJ. HIV infection of the central nervous system is characterized by rapid turnover of viral RNA in cerebrospinal fluid. J Acquir Immun Defic Syndr Hum Retrovirol 1999, 20:259-264.
27. Cinque P, Presi S, Bestetti A, Racca S, Pierotti C, Morelli P, et al. Effect of genotypic resistance on the virologic response to highly active antiretroviral therapy in cerebrospinal fluid. AIDS Res Hum Retroviruses 2001, 5:377-383.
28. Stingele K, Haas J, Zimmermann T, Stingele R, Hubsch-Muller C, Freitag M, et al. Independent HIV replication in paired CSF and blood viral isolates during antiretroviral therapy. Neurology 2001, 56:355-361.
29. DeLuca A, Ciancio BC, Larussa D, Murri R, Cingolani A, Rizzo MG, et al. Correlates of independent HIV-1 replication in the CNS and of its control by antiretrovirals. Neurology 2002, 59:342-347.
30. Centers for Disease Control and Prevention. Guidelines for using antiretroviral agents among HIV-infected adults and adolescents: recommendation of the Panel on Clinical Practices for Treatment of HIV. MMWR 2002, 51(No. RR-7):1-55.
31. Yeni PG, Hammer SM, Carpenter CCJ, Cooper DA, Fischl MA, Gatell JM, et al. Antiretroviral Treatment for Adult HIV Infection in 2002 Updated Recommendations of the International AIDS Society-USA Panel. JAMA 2002, 288:222-235.